Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism
2 other identifiers
observational
240
1 country
1
Brief Summary
Clustering of various metabolic parameters including abdominal obesity, hyperglycaemia, low high-density lipoprotein cholesterol, elevated triglycerides and hypertension have been used worldwide as metabolic syndrome to predict cardiometabolic risk. Thyroid dysfunction impacts on various levels of these components. Recent evidence from HepG2 cells indicates that betatrophin, also known as TD26/RIFL/lipasin/ANGPTL8/C19orf80, a secreted protein that regulates glucose, lipid metabolism, and energy homeostasis, is induced by T3. However, the role of betatrophin in hyperthyroid patients is unknown. The objective was to study serum betatrophin levels in hyperthyroid patients and the association of serum betatrophin levels with hyperthyroidism.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2016
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 20, 2016
CompletedFirst Posted
Study publicly available on registry
June 24, 2016
CompletedStudy Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2017
CompletedJuly 6, 2016
July 1, 2016
8 months
June 20, 2016
July 5, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Serum betatrophin levels
Change from baseline at 3 months
Secondary Outcomes (6)
Thyroid function index
At baseline and at the end of the third month
blood lipid profile
At baseline and at the end of the third month
liver function index
At baseline and at the end of the third month
hypersensitive c-reactive protein (hs-CRP)
At baseline and at the end of the third month
Blood glucose
At baseline and at the end of the third month
- +1 more secondary outcomes
Study Arms (2)
Hyperthyroid Patients
Patients with hyperthyroidism
NC group
Normal control subjects
Interventions
Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
Eligibility Criteria
Patients with hyperthyroidism would be recruited from the Department of Endocrinology, the First People's Hospital of Xuzhou, from May, 2016, to May, 2017. During the same period, the healthy controls would be selected.
You may qualify if:
- Clinical diagnosis of hyperthyroidism
- Must be drug-naive before recruitment
You may not qualify if:
- diabetes
- hypertension
- cancer
- pregnancy
- lactation
- subacute thyroiditis
- postpartum thyroiditis
- abnormal liver function
- abnormal kidney function
- infectious diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Hu Haolead
Study Sites (1)
The First People's Hospital of Xuzhou,
Xuzhou, Jiangsu, 221000, China
Related Publications (8)
Lopez D, Abisambra Socarras JF, Bedi M, Ness GC. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim Biophys Acta. 2007 Sep;1771(9):1216-25. doi: 10.1016/j.bbalip.2007.05.001. Epub 2007 May 21.
PMID: 17572141BACKGROUNDRibeiro MO, Carvalho SD, Schultz JJ, Chiellini G, Scanlan TS, Bianco AC, Brent GA. Thyroid hormone--sympathetic interaction and adaptive thermogenesis are thyroid hormone receptor isoform--specific. J Clin Invest. 2001 Jul;108(1):97-105. doi: 10.1172/JCI12584.
PMID: 11435461BACKGROUNDDong XY, Pang XW, Yu ST, Su YR, Wang HC, Yin YH, Wang YD, Chen WF. Identification of genes differentially expressed in human hepatocellular carcinoma by a modified suppression subtractive hybridization method. Int J Cancer. 2004 Nov 1;112(2):239-48. doi: 10.1002/ijc.20363.
PMID: 15352036BACKGROUNDQuagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19751-6. doi: 10.1073/pnas.1217552109. Epub 2012 Nov 12.
PMID: 23150577BACKGROUNDRen G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte-enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012 Aug 1;303(3):E334-51. doi: 10.1152/ajpendo.00084.2012. Epub 2012 May 8.
PMID: 22569073BACKGROUNDZhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012 Aug 10;424(4):786-92. doi: 10.1016/j.bbrc.2012.07.038. Epub 2012 Jul 15.
PMID: 22809513BACKGROUNDYi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013 May 9;153(4):747-58. doi: 10.1016/j.cell.2013.04.008. Epub 2013 Apr 25.
PMID: 23623304BACKGROUNDTseng YH, Ke PY, Liao CJ, Wu SM, Chi HC, Tsai CY, Chen CY, Lin YH, Lin KH. Chromosome 19 open reading frame 80 is upregulated by thyroid hormone and modulates autophagy and lipid metabolism. Autophagy. 2014 Jan;10(1):20-31. doi: 10.4161/auto.26126. Epub 2013 Nov 11.
PMID: 24262987RESULT
Related Links
Biospecimen
Plasma samples
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Wang Zhaoling, BD
The First People's Hospital of Xuzhou
- STUDY DIRECTOR
Hu Hao, MD
The First People's Hospital of Xuzhou
- PRINCIPAL INVESTIGATOR
Gao Zhaohua, MD
The First People's Hospital of Xuzhou
- PRINCIPAL INVESTIGATOR
Zhou Tingting, MD
The First People's Hospital of Xuzhou
- PRINCIPAL INVESTIGATOR
Yin Wenwen, MD
The First People's Hospital of Xuzhou
- PRINCIPAL INVESTIGATOR
Cai Ruonan, MD
The First People's Hospital of Xuzhou
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 3 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Deputy Director, Department of endocrinology, Principal Investigator, Clinical Associate Professor
Study Record Dates
First Submitted
June 20, 2016
First Posted
June 24, 2016
Study Start
July 1, 2016
Primary Completion
March 1, 2017
Study Completion
June 1, 2017
Last Updated
July 6, 2016
Record last verified: 2016-07
Data Sharing
- IPD Sharing
- Will share
The investigators are committed to the open and timely dissemination of the research outcomes. Plans for sharing resources with the scientific community include presentations and publications in peer-reviewed journals. The final data set will be made available to the public upon completion of the study.